- Home
- KLRA vs FRNM Comparison
KLRA vs FRNM Comparison
Compare KLRA & FRNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$12.75
HOLD
Current Price
$12.78
Company Overview
Basic Information| Metric | KLRA | FRNM |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2026 | 2024 |
Fundamental Metrics
Financial Performance| Metric | KLRA | FRNM |
|---|---|---|
| Price | $12.75 | $12.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $42.40 | $18.00 |
| AVG Volume (30 Days) | ★ 1.3M | 649.6K |
| Earning Date | 11-23-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $236.79 |
| Revenue Next Year | N/A | $11.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.76 | $9.97 |
| 52 Week High | $23.82 | $17.50 |
Technical Indicators
Market Signals| Indicator | KLRA | FRNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 40.49 |
| Support Level | $9.76 | $11.63 |
| Resistance Level | $19.15 | $17.32 |
| Average True Range (ATR) | 0.86 | 1.13 |
| MACD | 0.44 | -0.17 |
| Stochastic Oscillator | 82.09 | 20.37 |
Price Performance
Historical Comparison KLRA
FRNM
About KLRA Kailera Therapeutics Inc. Common Stock
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.